Acetylcysteine

Overview

Acetylcysteine (N-acetylcysteine, NAC) is a thiol-containing compound widely used in veterinary medicine as both an antidote and a mucolytic agent. Its primary clinical role is in the treatment of acetaminophen toxicity and other hepatotoxic conditions in which glutathione depletion or oxidative stress plays a central role.

In addition to its antidotal properties, acetylcysteine is used for its mucolytic effects within the respiratory tract, where it helps reduce the viscosity of pulmonary secretions. It has also been used in a variety of species and routes for specialized indications, including topical ophthalmic use, intrauterine and guttural pouch instillation in horses, and enemas in neonatal foals.

Mechanism of Action (MOA): Acetylcysteine acts as a precursor to glutathione, enhancing intracellular glutathione synthesis and functioning as a free radical scavenger. In cases of acetaminophen hepatotoxicity, this allows toxic metabolites to be detoxified via nontoxic pathways. In the respiratory tract, its free sulfhydryl group disrupts disulfide bonds in mucoproteins, reducing mucus viscosity and facilitating clearance.

Indications

Acetylcysteine is used in veterinary medicine for its antidotal, mucolytic, and antioxidant properties. Its indications vary by species, route of administration, and underlying condition.

• Acetaminophen toxicity (dogs and cats):
  Primary treatment to restore or maintain glutathione levels and limit hepatocellular injury following acetaminophen exposure.
• Other toxicities associated with oxidative stress:
  Used as an antidote or adjunctive therapy for xylitol, phenol, phenazopyridine, cadmium, mushroom, sago palm, and doxorubicin-induced hepatotoxicity.
• Mucolytic therapy (pulmonary disease):
  Administered via nebulization or intratracheal routes to reduce viscosity of respiratory secretions and facilitate airway clearance.
• Ophthalmic use (topical):
  Used to inhibit collagenase and proteinase activity in corneal disease to slow or prevent corneal melting.
• Degenerative myelopathy in dogs (adjunctive, anecdotal):
  Used orally in combination with aminocaproic acid; clinical efficacy has not been established.
• Equine applications:
  • Strangles: Instilled into the guttural pouch to help dissolve chondroids and reduce the need for surgical removal.
  • Neonatal foals: Used as an enema to soften and evacuate meconium refractory to repeated enemas.
  • Mares in estrus: Intrauterine instillation as an adjunctive treatment for endometritis to reduce inflammation and improve pregnancy rates.

Dosage (Reference)

Dog / Cat

In dogs and cats, acetylcysteine is primarily used to restore or maintain glutathione levels in cases of acetaminophen toxicity or other hepatotoxic conditions associated with oxidative damage. Intravenous administration is preferred in severe intoxications or when oral dosing is not feasible.

Dog (Special Use)

Acetylcysteine has been used anecdotally as part of a multimodal protocol for canine degenerative myelopathy; however, clinical efficacy has not been demonstrated in published trials.

Cat (Special Use)

In cats with hepatic lipidosis, acetylcysteine may be used as an adjunctive therapy alongside nutritional support and treatment of the underlying cause.

Warnings & Precautions

Acetylcysteine is generally considered safe when used appropriately; however, route of administration, dilution requirements, and patient respiratory status must be carefully considered to avoid adverse reactions.

• Pulmonary hypersensitivity: Inhalational (nebulized) administration may cause bronchospasm, chest tightness, or airway irritation. Use with extreme caution, or avoid entirely, in animals with bronchospastic conditions such as asthma or chronic bronchitis.
• No contraindications as an antidote: When used for treatment of toxicities (eg, acetaminophen toxicity), acetylcysteine has no absolute contraindications.
• Dilution requirement: Oral and IV formulations must be diluted to a final concentration of 5% (50 mg/mL) prior to administration.
• Intravenous use precautions: Acetylcysteine is not labeled for IV use, but is commonly used anecdotally. When administered IV, a 0.2 micron in-line filter must be used, and the drug should be given slowly to reduce the risk of adverse reactions.
• Unpleasant odor and taste: The sulfurous smell and taste can make oral administration difficult. Gastric tubes are often required to ensure accurate dosing, especially in critical patients.
• Inhalation solution used IV: If an inhalation formulation is used for IV administration, appropriate filtration and dilution are mandatory to avoid particulate-related complications.
• Respiratory monitoring: Animals receiving nebulized acetylcysteine should be closely monitored for coughing, wheezing, dyspnea, or increased airway resistance.

Drug Interactions

Clinically significant drug interactions with acetylcysteine are limited; however, certain combinations may reduce efficacy or increase the risk of adverse effects and should be considered during treatment planning.

• Activated charcoal: Use as a gastrointestinal adsorbent in acetaminophen toxicity is controversial, as activated charcoal may also adsorb orally administered acetylcysteine and reduce its effectiveness.
• Nitroglycerin: Concurrent IV administration may enhance hypotensive effects; monitor blood pressure closely if used together.

Side Effects & Overdose

Side Effects

Adverse effects associated with acetylcysteine are generally related to the route of administration and are usually mild to moderate in severity. Most reactions are manageable with supportive care.

• Gastrointestinal effects (oral use): Nausea and vomiting are the most commonly reported adverse effects when used for treatment of acetaminophen toxicity; urticaria has been reported rarely.
• Intravenous administration: IV use is generally well tolerated in veterinary patients. In humans, IV boluses have been associated with transient blood pressure changes (hyper- or hypotension), flushing, erythema, gastrointestinal upset, and hypersensitivity reactions such as rash or wheezing.
• Inhalational administration: Nebulization or intratracheal administration may cause bronchoconstriction, chest tightness, stomatitis, coughing, airway irritation, or hypersensitivity reactions.
• Respiratory effects in cats: Endotracheal nebulization has been associated with increased airway resistance, increased secretions, coughing, and occasional neurologic signs (eg, unilateral strabismus) in cats with experimentally induced asthma.
• Residue after nebulization: A sticky residue may be observed on the face following mask nebulization; this is cosmetic and not clinically significant.

Overdose

Acetylcysteine has a wide margin of safety, and serious toxicity is uncommon even in overdose situations.

• Acute toxicity: Reported LD₅₀ values in dogs are approximately 1 g/kg (oral) and 700 mg/kg (IV).
• Clinical concern: Most overdose-related effects mirror known adverse reactions rather than causing unique toxic syndromes.
• Management: Treatment is supportive and based on clinical signs; monitoring of cardiovascular, respiratory, and neurologic status is recommended.
• Consultation: For suspected or confirmed overdose, consultation with a 24-hour veterinary poison control center is recommended.

Key Notes

Practical clinical considerations to optimize the safe and effective use of acetylcysteine in veterinary patients:

• Time-sensitive antidote: Clinical benefit is greatest when acetylcysteine is administered as early as possible following toxin exposure, particularly in acetaminophen intoxication.
• Multiple mechanisms of benefit: In addition to glutathione replenishment, acetylcysteine provides antioxidant effects and improves hepatic perfusion, supporting liver recovery.
• Route selection matters: Choice of administration route (IV, PO, inhalational, topical, or local instillation) depends on indication and patient stability rather than convenience.
• Extra-label versatility: Acetylcysteine is widely used extra-label across multiple species and organ systems, emphasizing the importance of clinician familiarity with dilution and handling.
• Adjunctive—not standalone—therapy: In most clinical scenarios, acetylcysteine should be used as part of a broader treatment protocol rather than as sole therapy.
• Clinical supervision required: Due to specialized preparation, dilution, and administration techniques, acetylcysteine use is best limited to controlled clinical settings.